| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
NOD-IN-1 is a novel and potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors with IC50 of 5.74 μM and 6.45 μM for NOD1 and NOD2, respectively. In the low micromolar range, it exhibited balanced inhibitory activity against both targets. NOD1 and NOD2 are significant members of the family of pattern recognition receptors and are essential for innate immunity. But several diseases have also been linked to overactivation of NODs, particularly NOD1. Unexpectedly, NOD1 continues to be a largely untapped target in this regard.
| Targets |
NOD1; NOD2
|
||
|---|---|---|---|
| ln Vitro |
NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2 with IC50 of 5.74 μM and 6.45 μM, respectively. NOD1 and NOD2 are significant members of the family of pattern recognition receptors and are essential for innate immunity. But several diseases have also been linked to overactivation of NODs, particularly NOD1. Unexpectedly, NOD1 continues to be a largely untapped target in this regard.
|
||
| ln Vivo |
|
||
| Enzyme Assay |
NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2 with IC50 of 5.74 μM and 6.45 μM, respectively.
|
||
| Cell Assay |
Noditinib-1 and the synthesized potential NOD1 inhibitor NOD-IN-1 are used to screen these compounds for potential cytotoxicity by measuring the proliferation rates of HEK-Blue NOD1 cells in the presence of these compounds. A compound of interest, up to a 25 M concentration, is applied to cells for 24 hours. Since the residual metabolic activities of the HEK-Blue NOD1 cells do not fall below 80% at the highest concentration tested, a comparison of the observed metabolic activities with those of the untreated control demonstrated that all compounds are well tolerated by HEK-Blue NOD1 cells[1].
|
||
| Animal Protocol |
|
||
| References |
| Molecular Formula |
C18H17NO4S
|
|
|---|---|---|
| Molecular Weight |
343.40
|
|
| Exact Mass |
343.397
|
|
| Elemental Analysis |
C, 62.96; H, 4.99; N, 4.08; O, 18.64; S, 9.34
|
|
| CAS # |
132819-92-2
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
CCOC(=O)C1=CC2=CC=CC=C2N1S(=O)(=O)C3=CC=C(C=C3)C
|
|
| InChi Key |
OJMOGUKIYRAILM-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C18H17NO4S/c1-3-23-18(20)17-12-14-6-4-5-7-16(14)19(17)24(21,22)15-10-8-13(2)9-11-15/h4-12H,3H2,1-2H3
|
|
| Chemical Name |
ethyl 1-(4-methylphenyl)sulfonylindole-2-carboxylate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9121 mL | 14.5603 mL | 29.1206 mL | |
| 5 mM | 0.5824 mL | 2.9121 mL | 5.8241 mL | |
| 10 mM | 0.2912 mL | 1.4560 mL | 2.9121 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Figure 2.Proliferation rates, expressed as metabolic activities, of HEK-Blue cells after 24h treatment with the synthesized compounds and Noditinib-1 (25μM).Bioorg Med Chem.2016 Nov 1;24(21):5221-5234. |
|---|
Figure 3. Effects of synthesized compounds 4–7, 9–12 and Noditinib-1 (1) on the inhibition of C12-iE-DAP-induced NF-κB transcriptional activity.Bioorg Med Chem.2016 Nov 1;24(21):5221-5234. |
Figure 4. Inhibition of C12-iE-DAP-induced NF-κB transcriptional activity bycompounds 4 (NOD-IN-1)and 39–43.Bioorg Med Chem.2016 Nov 1;24(21):5221-5234. |
Figure 5. Effects of compounds 9 and 13–19 on the inhibition of C12-iE-DAP-induced NF-κB transcriptional activity.Bioorg Med Chem.2016 Nov 1;24(21):5221-5234. |
|---|
Figure 6. Inhibition of C12-iE-DAP-induced NF-κB transcriptional activity by compounds 12, 33–38, 44 and 45.Bioorg Med Chem.2016 Nov 1;24(21):5221-5234. |
Figure 1. The design of novel NOD1 inhibitors based on structures of 1 (Noditinib-1) and 2.Bioorg Med Chem.2016 Nov 1;24(21):5221-5234. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
